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Parkinson’s disease (PD) is a neurodegenerative disorder of unknown etiology. The main
treatment of PD consists of medication with dopamine-based drugs, which palliate the
symptoms but may produce adverse effects after chronic administration. Accordingly,
there is a need to develop novel neuroprotective therapies. Several studies suggest
that omega-3 polyunsaturated fatty acids (n-3 PUFA) might provide protection against
brain damage. Here, we studied several experimental models of PD, using striatal
neuronal cultures, striatal slices, and mice, to assess the neuroprotective effects of
docosahexaenoic acid (DHA), the main n-3 PUFA in the brain, administered in its
triglyceride form (TG-DHA). Hence, we determined the beneficial effects of TG-DHA
on neural viability following 6-hydroxydopamine (6-OHDA)-induced neurotoxicity, a well-
established PD model. We also implemented a novel mouse behavioral test, the beam
walking test, to finely assess mouse motor skills following dopaminergic denervation.
This test showed potential as a useful behavioral tool to assess novel PD treatments.
Our results indicated that TG-DHA-mediated neuroprotection was independent of the
net incorporation of PUFA into the striatum, thus suggesting a tight control of brain lipid
homeostasis both in normal and pathological conditions.
Keywords: docosahexaenoic acid, Parkinson’s disease, beam walking test, motor coordination, balance,
omega-3 polyunsaturated fatty acids
INTRODUCTION
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s
disease, and affects approximately 1% of individuals over the age of 60 (de Lau and Breteler,
2006). The main clinical features of PD include asymmetric onset of bradykinesia (slowness to
initiate voluntary movements with progressive reduction in speed and amplitude of repetitive
actions), rigidity, resting tremor, and posture instability (Meissner et al., 2011). All these symptoms
may appear after the selective death of approximately 60% of striatal dopaminergic afferent
fibers arising from the substantia nigra pars compacta (Braak and Del Tredici, 2008). The
principal therapeutic approach to PD management since the 1970s has been to restore striatal
levels of dopamine by means of the precursor L-3,4-dihydroxyphenylalanine (L-DOPA) or other
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dopaminergic agonists (Poewe, 2009). However, this kind of
treatment is only palliative, and chronic consumption of
dopamine-based drugs may also induce a number of adverse
effects (i.e., L-DOPA induced dyskinesia) (Huot et al., 2013).
Consequently, research has also focused on going beyond
symptomatic treatments in the quest for neuroprotective agents
that may impede or delay disease progression.
The etiology of PD is not fully known. Although genetic
and environmental factors have both been described as possible
causes for PD, a complete explanation of the pathogenesis of
this disorder is still lacking (Puschmann, 2013; Ascherio and
Schwarzschild, 2016). Nevertheless, it is well established that
some of the mechanisms that lead to PD include oxidative stress,
mitochondrial dysfunction, and/or inflammation (Schapira,
2008; Laye, 2010; Blesa et al., 2015). Accordingly, a number of
agents including caffeine, nicotine, coenzyme Q10, and omega-3
polyunsaturated fatty acids (n-3 PUFA) have been proposed to
counteract these processes (Müller et al., 2003; da Silva et al.,
2008; Quik et al., 2009; Prediger, 2010; Seidl and Potashkin,
2011). Of these, n-3 PUFA represent one of the most challenging
molecules, since they are not only natural dietary substances,
but they are also essential components of neuronal membranes,
and are known to be involved in the inflammatory response
to tissue damage. Thus, a potential anti-inflammatory role
for n-3 PUFA has been proposed, based on their capacity
to inhibit brain cyclooxygenase or to improve mitochondrial
respiratory function (Massaro et al., 2006; Stanley et al., 2012). In
support of this notion, an anti-inflammatory effect of n-3 PUFA
supplementation in older individuals has been demonstrated;
for instance, administration of fish oil-based lipid emulsions
was observed to increase circulating levels of anti-inflammatory
cytokines (Barros et al., 2013; Berger et al., 2013).
In addition, epidemiological and pre-clinical data alike point
to neuroprotective effects of n-3 PUFA in neurodegenerative
disorders. The most abundant n-3 PUFA in the brain,
docosahexaenoic acid (DHA), is also one of the most extensively
studied (Dyall, 2015), and several studies conducted in PD animal
models have reported the beneficial effects of DHA. For example,
DHA administration reduced L-DOPA-induced dyskinesia in
parkinsonian monkeys (Wurtman et al., 2006), and DHA dietary
supplementation reduced apoptosis of dopaminergic cells in the
brain of MPTP-treated mice (Bousquet et al., 2008). Besides pre-
clinical data, there is also some information on the use of DHA
in humans, although large, well-designed intervention studies on
the effects of DHA in normal aging and in neurodegenerative
disorders are still lacking (Dyall, 2015). Nevertheless, a recent
clinical trial studied the role of DHA in reducing dyskinesia in PD
(ClinicalTrials.gov identifier: NCT01563913), while in another
study it was found that DHA supplementation correlated well
with a lower risk of depression associated with PD (da Silva et al.,
2008). Further data in the literature also support a role for DHA
supplementation in the management of depression and cognitive
impairments. Thus, several studies have reported that intake of
dietary n-3 PUFA is associated with a lower risk of depression
(for review see Grosso et al., 2016), and similarly, that there is
an inverse correlation between n-3 PUFA intake and age-related
cognitive decline (for review see Pusceddu et al., 2016).
Overall, DHA and other natural dietary substances show
potential as adjunctive therapies for PD, since they may exert
neuroprotective effects. Here, we aimed to provide a pre-clinical
paradigm by using the well-known 6-hydroxydopamine (6-
OHDA)-PD model together with a novel behavioral test (beam
walking test), which may serve to assess the potential of these
molecules to improve PD treatment.
MATERIALS AND METHODS
Reagents
Triglyceride of docosahexaenoic acid (TG-DHA) obtained by
enzymatic synthesis was kindly supplied by Brudy Technology
(Barcelona, Spain). This oil contains more than 70% TG-
DHA and more than 90% of ω-3 of total fatty acids
(Mancera et al., 2017). The stock TG-DHA solution in
100% ethanol was diluted with the indicated aqueous buffer
before use. All other compounds were obtained from external
sources: 6-hydroxydopamine (6-OHDA) (Sigma-Aldrich, St.
Louis, MO, United States) and 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide tetrazolium (MTT) (Sigma-
Aldrich). The primary antibodies used were rabbit anti-TH
polyclonal antibody (Millipore, Temecula CA, United States)
and rabbit anti-α-actinin-1 polyclonal antibody (Santa Cruz
biotechnology, Dallas TX, United States). The secondary
antibodies used were horseradish peroxidase (HRP)-conjugated
goat anti-rabbit IgG (Pierce Biotechnology, Rockford, IL, United
Staes) and Alexa Fluor 488-conjugated donkey anti-rabbit IgG
(Jackson ImmunoResearch Laboratories Inc., West Grove, PA,
United States).
Animals
CD-1 wild-type mice (weight 22–27 g), either males or females,
from the University of Barcelona animal facility were used.
Interestingly, no significant effect of sex was found in the
subsequent experiments using animals. The University of
Barcelona Committee on Animal Use and Care approved the
study protocol. Animals were housed and tested in compliance
with the guidelines given in the Guide for the Care and
Use of Laboratory Animals (Clark et al., 1997) and following
European Union directives (2010/63/EU). Every effort was made
to minimize animal suffering and the number of animals used.
Animals were housed in groups of five in standard cages with
ad libitum access to food and water and maintained under
controlled standard conditions (12 h dark/light cycle starting
at 7:30 am, 22◦C temperature, and 66% humidity). Behavioral
testing was performed and between 2 pm and 7 pm, in mice aged
2–3 months.
Striatal Slices and MTT Assay
Mouse brain was removed and placed in ice-cold KREB-
saline buffer (124 mM NaCl, 4 mM KCl, 1.5 mM CaCl2,
1.5 mM MgSO4, 1.25 mM KH2PO4, 10 mM D-glucose, and
26 mM NaHCO3) bubbled with 95% O2 up to pH 7.4. Brain
slices (300 µm) were rapidly prepared using a Leica VT1200
vibratome (Leica Lasertechnik GmbH, Heidelberg, Germany).
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The striatum was dissected in KREBs buffer at 4◦C and
allowed to recover for 30 min in KREBs buffer at 37◦C.
Subsequently, striatal slices were incubated with the indicated
6-OHDA concentration in the absence or presence of TG-
DHA in KREBs buffer at 37◦C and toxicity was evaluated
by measuring cell uptake of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT ), as previously described
(Liu et al., 1997). The tetrazolium ring of MTT is cleaved by
active dehydrogenases in living cells to produce a precipitated
formazan salt that is solubilized by DMSO to give a colored
compound. After stirring the mixture for 5 min, optical density
was measured at 540 nm in a POLARstar plate reader (BMG
Labtech, Durham, NC, United States) to determine cell death
rates.
Striatal Neuronal Cultures
Primary striatal neurons were cultured from E18 CD-1 mouse
embryos. Briefly, after dissection, the striatum was treated with
1.25% trypsin (Sigma-Aldrich) for 10 min and mechanically
dissociated with a flame-polished Pasteur pipette. Neurons were
plated onto poly-D-lysine-coated (0.1 mg/mL) and laminin-
coated (0.01 mg/mL) wells at a density of 80,000 cells/cm2
on a 96-well plate in minimum essential medium (Invitrogen,
Carlsbad, CA, United States) supplemented with 10% horse
serum, 10% bovine serum, 1 mM pyruvic acid, and 0.59% glucose.
After 4–14 h, the medium was substituted with Neurobasal
medium supplemented with penicillin (100 U/mL), streptomycin
(100 µg/mL), 0.59% glucose, and B27 supplement (Invitrogen
Carlsbad). Neurons were maintained at 5% CO2, 37◦C, and 95%
humidity for 11 days. Subsequently, neurons were treated with
increasing concentrations (0, 10, 50, and 100 µM) of TG-DHA
growing medium for 3 days. Next, neurons were incubated with
6-OHDA (500 µM) for 24 h. Neuronal death was assessed by
MTT assay (see above).
Surgery
Experimental parkinsonism was induced in mice by
means of bilateral striatal lesion as previously described
(Fernández-Dueñas et al., 2014). In brief, mice were
anesthetized with a ketamine/xylazine combination (75 mg/kg
ketamine hydrochloride/10 mg/kg xylazine hydrochloride,
intraperitoneally) (Merial Laboratorios S.A. Barcelona, Spain
and Laboratorios Calier S.A. Barcelona, Spain, respectively)
and immobilized in an adapted digital lab stereotaxic device
(Stoelting Co., Wood Dale, IL, United States). Then, an incision
(0.5 cm) was performed in the skin of the skull to bilaterally
lesion both the right and the left striatum with 6-OHDA (8 µg
of 6-OHDA in 4 µl of saline solution containing 0.05% ascorbic
acid; Sigma-Aldrich, St Luis, MO, United States). Following
the mouse atlas (Franklin and Paxinos, 2008), the stereotaxic
coordinates with respect to the bregma were: AP = 1.0 mm,
ML = ± 1.7 mm, and DV = −3.5 mm. The 6-OHDA solution
was injected manually at a rate of 1 µl/min, and after injection,
the needle was left in place for 5 min before retracting it slowly to
prevent reflux. Mice were then quickly warmed and returned to
their cages. In addition, a similar number of mice were injected
with vehicle (saline) and used as a control to discriminate the
possible effects of surgery. After surgery, animals (vehicle- and
6-OHDA-lesioned) were treated either with intragastric (i.g.)
vehicle (0.5% methylcellulose and 2% DMSO) or TG-DHA
(250 mg/kg) for 22 consecutive days (Figure 2A). Blood samples
were obtained after fasting (8–12 h) by cardiac puncture and
centrifuged to separate the plasma fraction from red blood
cells (RBCs). The cortex and striatum were dissected, and
total membrane extracts obtained as described below. Plasma
and membrane extracts from RBCs, cortex, and striatum were
immediately frozen and stored at−80◦C until used for lipidomic
analyses.
Immunohistochemistry
Mice were fixed and coronal brain sections (50–70 µm)
obtained as previously described (Taura et al., 2015). Slices
were collected in Walter’s Antifreezing solution (30% glycerol,
30% ethylene glycol in PBS, pH 7.2) and kept at −20◦C
until processing. On the day of the experiment, slices were
washed three times in PBS, permeabilized with 0.3% Triton
X-100 in PBS for 2 h and rinsed again three more times
with wash solution (0.05% Triton X-100 in PBS). The slices
were then incubated with blocking solution (10% NDS in
wash solution; Jackson ImmunoResearch Laboratories Inc.) for
2 h at R.T. and subsequently incubated overnight with the
primary antibodies at 4◦C. After two rinses (10 min each) with
1% NDS in wash solution, sections were incubated for 2 h
at R.T. with the appropriate secondary antibodies conjugated
with Alexa dyes (Invitrogen, Carlsbad, CA, United States),
then washed (10 min each) twice with 1% NDS in wash
solution, twice more with PBS, and mounted on slides.
Fluorescence striatal images were captured using a Leica TCS 4D
confocal scanning laser microscope (Leica Lasertechnik GmbH,
Heidelberg, Germany).
Fatty Acid Analysis
Fatty acid composition was determined using the method
described by Lepage and Roy (Lepage and Roy, 1986). Total
lipids, containing 0.01% butylhydroxytoluene as antioxidant,
were transesterified with acetyl chloride for 60 min at 373 K.
Gas chromatography analysis was performed using a Shimadzu
GCMS-QP2010 Plus gas chromatograph-mass spectrometer
(Shimadzu, Kyoto, Japan). Fatty acid methyl ester peaks
were identified by their elution pattern and relative retention
times with respect to a reference mixture (GLC-744 Nu-
Chek Prep. Inc., Elysian MN, United States). The results were
expressed in relative amounts (molar percentage of total fatty
acids). For specific fatty acids, the following indexes were
calculated as previously described (Cacabelos et al., 2014; de
Luis et al., 2016): saturated fatty acids (SFA) = 6mol% of
SFA; unsaturated fatty acids (UFA) = 6mol% of unsaturated
fatty acids; monounsaturated fatty acids (MUFA) = 6mol%
of monoenoic fatty acids; polyunsaturated fatty acids series
n-3 (PUFA n-3) = 6mol% of polyunsaturated fatty acids
n-3 series; polyunsaturated fatty acids series n-6 (PUFA n-
6) = 6mol% of polyunsaturated fatty acids n-6 series; n-6/n-3
ratio= (6mol% of PUFA n-3)/(6mol% of PUFAn-6); AA/DHA
ratio = (mol% (20:4n-6)/(mol% of 22:6n-3); peroxidizability
Frontiers in Neuroscience | www.frontiersin.org 3 August 2018 | Volume 12 | Article 604
fnins-12-00604 August 27, 2018 Time: 10:24 # 4
Gómez-Soler et al. Omega-3 & Parkinsonism
index (PI) = [(0.025 × 6mol% monoenoic) + (1 × 6mol%
dienoic) + (2 × 6mol% trienoic) + (4 × 6mol% tetraenoic) +
(6 × 6mol% pentaenoic) + (8 × 6mol% hexaenoic)]; double
bond index (DBI) = (6mol% monoenoic × 1) + (6mol%
dienoic× 2)+ (6mol% trienoic× 3)+ (6mol% tetraenoic× 4)
+ (6mol% pentaenoic × 5) + (6mol% hexaenoic × 6); anti-
inflammatory index (AI) = [6mol% of (20:3n-6) + (20:5n-3) +
(22:5n-3)+ (22:6n-3)]/[mol% (20:4n-6)].
Membrane Preparation
Striatal membranes were prepared as previously described
(Fernández-Dueñas et al., 2015). In brief, the striatum was
dissected and rapidly homogenized in ice-cold 10 mM Tris–
HCL (pH 7.4), 1 mM EDTA, and 300 mM KCl buffer with
Polytron at setting five for three periods of 10 s each. The
homogenate was centrifuged for 10 min at 1000 × g and the
resulting supernatant centrifuged again for 30 min at 12000 × g.
The pellet was resuspended in the same buffer, and protein
content was determined by means of the Bradford assay (Pierce
Biotechnology).
Gel Electrophoresis and Immunoblotting
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS/PAGE) was performed using 10% polyacrylamide gels.
Proteins were transferred to PVDF membranes using a
semidry transfer system and immunoblotted with the indicated
primary antibody and then HRP-conjugated goat anti-rabbit
IgG (1:30000). The immunoreactive bands were visualized using
a chemiluminescent detection kit (Pierce Biotechnology) and
an Amersham Imager 600 (GE Healthcare Europe GmbH,
Barcelona, Spain).
Beam Walking Test
We assessed the motor coordination and balance of mice by
measuring their ability to traverse a narrow beam to reach an
enclosed safety platform (Luong et al., 2011). The beam consisted
of a long strip of wood (1 m) with a variable width ranging
from 28 to 5 mm. The beam was placed in an inclined position,
with one end mounted on a 50-cm high narrow support and the
other end attached to an enclosed box on a 100-cm high narrow
support. During training, mice were placed at the start of the
beam and trained over 2 days to traverse the beam to the enclosed
box. Once the mice were trained, they performed one trial and the
time to traverse the beam was quantified and registered. This test
is particularly useful for detecting subtle deficits in motor skills
and balance that may not be detected by other motor tests, such
as the Rotarod test (Luong et al., 2011).
Statistics
Data are represented as means ± S.E.M. Comparisons among
experimental groups were performed by Student’s t-test, one-way
ANOVA with Dunnett’s or Tukey’s post hoc test, or by two-way
ANOVA followed by Bonferroni’s post hoc test using GraphPad
Prism 6.01 (San Diego, CA, United States), as indicated. Statistical
difference was accepted when P < 0.05. Linear logistic regression
and correlation analysis were performed in selected experiments.
RESULTS
TG-DHA Reduced 6-OHDA-Mediated
Neurotoxicity in vitro and ex vivo
The main aim of the present study was to evaluate the possible
neuroprotective effects of DHA in several experimental models
of PD. To this end, in cell, in vitro, and ex vivo experimental
models of parkinsonism were implemented. First, we studied
the capacity of TG-DHA to reverse 6-OHDA-induced toxicity
in striatal primary cultures and striatal slices. 6-OHDA has been
widely used to damage dopaminergic neurons in vitro (Ding et al.,
2004), thus we expected to obtain valuable information regarding
the TG-DHA dosages to employ in subsequent experimental
models. We first evaluated cell viability of striatal slices after
challenging them with increasing concentrations of 6-OHDA for
4 h. As shown in Figure 1A, cell death was dose-dependently
induced by 6-OHDA, from which we selected 0.5 mM for further
experiments. We also determined the time-course of 6-OHDA-
induced ex vivo cell death in order to select the most appropriate
incubation time. As shown in Figure 1B, the maximal effect of
6-OHDA was observed 4 h after incubation. Having established
the 6-OHDA dose and incubation time, we next investigated
the capacity of TG-DHA to block or attenuate cell death.
Accordingly, we incubated slices with 6-OHDA (0.5 mM for 4 h)
in the absence or presence of increasing concentrations of TG-
DHA and found that TG-DHA dose-dependently promoted cell
viability after 6-OHDA treatment, although it did not completely
preclude induced cell death (Figure 1C). Based on the results
obtained in striatal slices, we also evaluated the effects of TG-
DHA co-incubation following 6-OHDA treatment in striatal
primary cultures. Our results indicated that again, TG-DHA
dose-dependently and partially blocked 6-OHDA-induced cell
toxicity in striatal primary cultures (Figure 1D).
TG-DHA Counteracted
6-OHDA-Mediated Neurotoxicity in Mice
Having determined the capacity of TG-DHA to partially
counteract 6-OHDA-mediated toxicity in vitro and ex vivo, we
studied an animal model of PD. To this end, we bilaterally
lesioned mice striatum by means of stereotaxic injection of 6-
OHDA, as previously described (Fernández-Dueñas et al., 2014),
and treated animals as indicated in Figure 2A. When assessing
TH distribution in the striatum, which corresponds to existing
dopaminergic neurons, we observed a considerable reduction in
immunostaining only in 6-OHDA treated animals, while TG-
DHA seemed to protect against the death of dopaminergic cells
(Figure 2B).
Next, we assessed TH expression in the striatum by
immunoblot analysis to quantify the extent of the lesion
and the possible neuroprotection mediated by TG-DHA
(Figure 3). Interestingly, while an effect of TG-DHA treatment
[F(1,44) = 58.4, P = 0.0199] was confirmed by two-way
ANOVA analysis of the data, no effect of 6-OHDA lesion
[F(1,44) = 3.1, P = 0.0853] or interaction between both factors
[F(1,44) = 3.349, P= 0.074] was observed. In addition, significant
differences (P < 0.05) in TH expression between vehicle- and
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FIGURE 1 | Neuroprotective effect of TG-DHA ex vivo following 6-OHDA treatment. (A) Striatal slices were treated either with vehicle (Veh) or increasing
concentrations of 6-OHDA (0.03-1 mM) for 4 h before neuronal death was determined by MTT assay. (B) Striatal slices were treated with 6-OHDA (0.5 mM) for 1, 2,
3, and 4 h before neuronal death was determined by MTT assay. (C) Striatal slices were treated with 6-OHDA (0.5 mM) for 4 h in the absence or presence of
increasing concentrations of TG-DHA (10–100 µM) before neuronal death was determined by MTT assay. (D) Striatal primary neurons were treated with 6-OHDA
(0.5 mM) for 24 h in the absence or presence of increasing concentrations of TG-DHA (10–100 µM) before neuronal death was determined by MTT assay. Results
are presented as means ± SEM of three independent experiments performed in triplicate. ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001 one-way ANOVA with Dunnett’s
post hoc test when compared to vehicle treatment (A,B) or Tukey’s post hoc test for multiple comparisons (C,D).
6-OHDA-lesioned mice were confirmed by Bonferroni’s post hoc
analysis. Accordingly, based on the different TH expression,
our results suggested that TG-DHA treatment protects against
6-OHDA-mediated toxicity.
Effects of TG-DHA Treatment on Fatty
Acid Profile in Mouse Striatum
Several studies have hypothesized that the possible
neuroprotective role of DHA may be explained by its capacity
to restore normal brain n-3 PUFA metabolism (Bousquet
et al., 2008; Lo Van et al., 2016). Accordingly, we next aimed
to assess possible changes in fatty acid composition caused
by administering TG-DHA in control and striatal 6-OHDA-
lesioned mice. First, we examined the fatty acid profile in two
brain areas, namely the striatum and cortex, of control and
striatal 6-OHDA-lesioned mice. In control animals, saturated
fatty acid content was significantly higher in the striatum, while
unsaturated, monounsaturated, and polyunsaturated fatty acid
content was higher in the cortex (Table 1). Thus, the amount of
DHA in the striatum was significantly lower than in the cortex
(Table 1), as previously reported (Létondor et al., 2014). In
addition, the PI, the DBI, and the AI were significantly reduced
in the striatum (Table 1). Since PI and DBI values could be
related to vulnerability to peroxidative damage, the low levels
of PI and DBI found in the striatum with respect to those
observed in the frontal cortex may indicate that the striatum
is especially sensitive to 6-OHDA-mediated neuronal damage,
because these membranes are actively producing substrates
for peroxidative modification. However, when evaluating the
fatty acid profile of striatal 6-OHDA-lesioned animals, no
differences were observed either in the striatum or the cortex
(Table 1). In addition, a possible effect of the 6-OHDA lesion
in the periphery, which could reflect some central effects,
was also examined by determining the lipid content found in
plasma and in total membrane extracts from RBC (Table 1).
We found that the striatal 6-OHDA lesion significantly reduced
PUFA and DHA levels in plasma of lesioned animals, but
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FIGURE 2 | TG-DHA precludes 6-OHDA-mediated reduction in striatal TH.
(A) Treatment schedule depicting the 6-OHDA lesion and the TG-DHA
administration regimen (250 mg/kg, i.g.) and behavioral testing (beam walking
test). (B) Photomicrographs showing immunohistochemistry detection of TH
in the striatum of vehicle- (saline) and 6-OHDA-lesioned mouse treated either
with vehicle (saline) or TG-DHA as shown in (A). Scale bar: 350 µm. CPu:
caudate putamen.
did not affect the lipid content of membrane extracts from
erythrocytes (Table 1). Furthermore, PI and DBI were only
significantly reduced in plasma of 6-OHDA-lesioned mice
(Table 1). These differences might be related to greater 6-
OHDA-mediated oxidation sensitivity of PUFA and DHA
when associated with plasmatic proteins and lipoproteins
(i.e., plasma) than when embedded in a biological membrane
(i.e., RBC). Overall, the striatal 6-OHDA lesion had no effect
on the fatty acid profile of the striatum, as recently reported
(Coulombe et al., 2016), but did modify plasma fatty acid
concentrations.
Subsequently, we assessed whether daily administration of the
TG-DHA of DHA for 22 days (Figure 2A) had any impact on the
PUFA profile of control and striatal 6-OHDA-lesioned animals.
Interestingly, while an effect of 6-OHDA lesion [F(1,16) = 15.46,
P < 0.01] and TG-DHA treatment [F(1,16) = 344.4, P < 0.0001]
on plasma DHA content was confirmed by two-way ANOVA
analysis of the data, no effect of the interaction between both
factors [F(1,16) = 0.064, P = 0.803] was observed (Figure 4A).
In addition, a significant reduction in plasma DHA content in
6-OHDA-lesioned animals, whether treated or untreated with
TG-DHA (P < 0.05; Figure 4A), was confirmed by Bonferroni’s
post hoc analysis. Similarly, while an effect of TG-DHA treatment
FIGURE 3 | TG-DHA effect on 6-OHDA-mediated neurotoxicity in mice.
Representative immunoblot showing TH immunoreactivity in striatal
membranes from vehicle- (Veh) and 6-OHDA-lesioned mice treated either with
vehicle (Veh) or TG-DHA (see Figure 2A). Striatal membranes were analyzed
by immunoblot (5 µg of protein/lane) using rabbit anti-TH (1 µg/ml) and rabbit
anti-α-actinin (1 µg/ml). The primary bound antibody was detected using a
HRP-conjugated goat anti-rabbit antibody (1/30,000). A representative blot of
four samples is shown. TH immunoreactive band intensities were measured
by densitometric scanning and normalized with respect to the corresponding
α-actinin immunoreactive band intensity for each sample. Results are
expressed as means ± SEM (n = 12 animals) relative to those for
vehicle-treated animals. ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001 two-way
ANOVA with Bonferroni’s post hoc test.
[F(1,16) = 94.5, P < 0.0001] on DHA content in RBC membranes
was confirmed by two-way ANOVA analysis of the data, no
effect of 6-OHDA lesion [F(1,16) = 0.015, P = 0.902], or the
interaction between both factors [F(1,16) = 0.064, P = 0.803],
was observed (Figure 4A). Neither the 6-OHDA lesion nor
the TG-DHA treatment had any effect on DHA content in
membranes from cortex and striatum (Figure 4A). Consequently,
following chronic TG-DHA treatment, a significant reduction
in the n-6/n-3 ratio was observed in plasma [F(1,16) = 172,
P < 0.0001] and RBC membranes [F(1,16) = 193.9, P < 0.0001],
but not in cortical or striatal membranes (Figure 4B). Overall,
these results show that 22 days of TG-DHA administration
prompted an increase in DHA content and a reduction in
the n-6/n-3 ratio in plasma and RBC membranes, but did
not alter the amount of DHA in membranes from cortex and
striatum.
TG-DHA Treatment Precluded
6-OHDA-Induced Locomotor Impairment
in Mice
According to the molecular data, 6-OHDA-lesioned mice
chronically treated with TG-DHA should present an improved
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TABLE 1 | Fatty acid composition of total lipids from plasma and total membrane extracts from red blood cell (RBC), cortex and striatum which were isolated from
control (Ctrl) and 6-OHDA lesioned mice.
% of Total fatty cids
Tissue: Plasma RBC Cortex Striatum
Mouse: Ctrl Lesioned Ctrl Lesioned Ctrl Lesioned Ctrl Lesioned
Fatty Acid:
SFA 35 ± 0.5 35.3 ± 0.2 52.6 ± 2 53.3 ± 2.9 50.7 ± 0.4 49.9 ± 1.3 75.6 ± 1.7UUU 73.3 ± 2.2
UFA 65 ± 0.5 64.7 ± 0.2 47.4 ± 2 46.7 ± 2.9 49.2 ± 0.4 50.1 ± 1.3 24.4 ± 1.7UUU 26.7 ± 2.2
MUFA 16.3 ± 1.8 20.8 ± 1.2 18.3 ± 0.8 18.9 ± 1 24.1 ± 0.4 23.8 ± 0.2 18.2 ± 0.8UUU 19.7 ± 0.3
PUFA 48.8 ± 1.3 ↓ 44 ± 1.2∗ 29.2 ± 2.1 27.8 ± 3.9 25.1 ± 0.6 26.3 ± 1.1 6.2 ± 1.1UUU 7 ± 2
PUFA n-6 45 ± 1.3 41 ± 1.3 26.5 ± 1.7 25.1 ± 3.2 11.7 ± 0.4 12.3 ± 0.4 4 ± 0.7UUU 4.4 ± 1.3
PUFA n-3 3.8 ± 0.09 ↓ 3 ± 0.2∗∗ 2.7 ± 0.3 2.7 ± 0.7 13.4 ± 0.3 14 ± 0.7 2.2 ± 0.4UUU 2.5 ± 0.7
n-6/n-3 ratio 12 ± 0.6 13.6 ± 1 10.4 ± 0.9 11.7 ± 2.5 0.9 ± 0.02 0.9 ± 0.03 1.9 ± 0.1UUU 1.9 ± 0.4
DHA 3 ± 0.1 ↓ 2.2 ± 0.2∗∗ 2.4 ± 0.3 2.4 ± 0.6 13.4 ± 0.3 14 ± 0.7 2.2 ± 0.4UUU 2.5 ± 0.7
DHA + EPA 3.1 ± 0.1 ↓ 2.3 ± 0.2∗∗ 2.4 ± 0.3 2.4 ± 0.6 13.4 ± 0.3 14 ± 0.7 2.2 ± 0.4UUU 2.5 ± 0.7
AA/DHA 4.6 ± 0.3 5.1 ± 0.4 5 ± 0.3 5.2 ± 0.7 0.6 ± 0.01 0.6 ± 0.02 1.6 ± 0.1UUU 1.6 ± 0.3
PI 120.3 ± 3.6 ↓ 101.3 ± 4∗∗ 89.6 ± 9.2 86 ± 16.3 152 ± 3.3 158.9 ± 7.6 32.4 ± 6UUU 37.6 ± 10.8
DBI 160 ± 2.5 ↓ 145.8 ± 3∗∗ 113.5 ± 8.1 109.5 ± 14.2 144 ± 1.9 148.8 ± 6 45.1 ± 5.4UUU 50.1 ± 8.4
AI 36.7 ± 3.8 35 ± 2 30.1 ± 2.1 31.2 ± 2.2 162 ± 4.3 163 ± 5.4 67.5 ± 5.3UUU 77 ± 17
Data are presented as mean ± S.E.M. (n = 5 animals). ∗P < 0.05 and ∗∗P < 0.01 Student nest when compared to its control group. UUUP < 0.001 Student’s t-test
when compared to cortex (control) group. SFA, saturated fatty acid; UFA, unsaturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid;
n-6, omega 6; n-3, omega 3; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; AA, arachidonic acid; PI, peroxidizability index; DBI, double bond index; AI,
anti-inflammatory index.
striatal function, since dopaminergic neurotransmission was less
damaged. In order to assess a behavioral output related to possible
alterations in motor skills, which are mainly controlled by the
striatal basal ganglia, we used a very sensitive model to determine
fine motor coordination and balance in mice and rats (Luong
et al., 2011). As shown in Figure 2A, mice were subjected to
the beam walking test, in which, after training, we measured
the time taken to cross the beam (see methods). We observed
that the 6-OHDA lesion significantly increased beam walking
time, thus corroborating alterations in motor skills in this mouse
model of PD (Figure 5A). However, 6-OHDA-lesioned mice
that received long-term TG-DHA treatment exhibited similar
beam walking times to wild-type mice, thus suggesting that
TG-DHA exerted neuroprotective effects as regards behavioral
function (Figure 5A). When TH expression and behavioral
performance (i.e., beam walking time) were plotted, a significant
inverse correlation was observed, yielding values of R2 × 0.97
(P < 0.05) and Pearson’s r = −0.98 (Figure 5B). Therefore,
by assessing beam walking time we could, in theory, gauge
the extent of dopaminergic innervation (i.e., TH expression).
Overall, TG-DHA treatment attenuated 6-OHDA-toxic effects
as assessed through TH expression and beam walking time
(Figure 5B).
DISCUSSION
Parkinson’s disease is a neurodegenerative condition of unknown
etiology, but plausible causes include oxidative stress and
inflammation. Many drugs and nutrients have been postulated
to prevent and/or palliate the processes associated with
neurodegenerative diseases. Of these, n-3 PUFA such as DHA
are among the most extensively studied. Here, we assessed
the neuroprotective effect of TG-DHA in its TG-DHA using
three different experimental models of parkinsonism: (i) primary
neuronal cultures from striatum (in vitro model); (ii) striatal
brain slices (ex vivo model); and (iii) 6-OHDA-lesioned animal
model of PD (in vivo model). Our results support the notion that
this molecule may represent a potential neuroprotective agent
for PD.
First, we evaluated the in vitro and ex vivo effect of
TG-DHA in primary striatal cultures and in striatal slices.
As previously shown (Ding et al., 2004), treatment with 6-
OHDA induced toxic effects in cells, which were partially
blocked by TG-DHA. Thus, TG-DHA exhibited a modest
but significant protective action in vitro and ex vivo. This
observation is consistent with a previous study in which we
showed that TG-DHA partially reversed induced cell death in
striatal slices and primary striatal cultures (Fernández-Dueñas
et al., 2017). Similarly, we recently observed that TG-DHA
increased cell viability in BV-2 microglia cells activated with
lipopolysaccharide and IFN-γ, although it only attenuated the
production of some pro-inflammatory mediators (Mancera et al.,
2017). A possible explanation for the relatively modest effects
of TG-DHA-mediated protection against cell death in vitro
might be that TG-DHA alters plasma membrane lipid turnover
and/or fluidity differently in vitro vs. in vivo. When assessing
DHA levels in control and 6-OHDA-lesioned mice, we did
not observe an accumulation of DHA in brain tissue. Thus,
we hypothesize that a dynamic turnover would better explain
the effects of TG-DHA supplementation. Therefore, rather
than producing an increase in fatty acid content, long-term
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FIGURE 4 | Effect of TG-DHA treatment on PUFA content. Control (Veh) and 6-OHDA-lesioned mice were administered with TG-DHA (250 mg/kg, i.g.) for 22 days
before DHA concentration (molar %) was determined from plasma, RBC membranes, cortex, and striatum (A). The PUFA n-6/n-3 ratio was also determined (B).
Data are presented as mean ± S.E.M. (n = 5 animals). ∗P < 0.05 and ∗∗∗P < 0.001 two-way ANOVA with Bonferroni’s post hoc test.
administration of TG-DHA might counterbalance 6-OHDA-
mediated oxidative damage and thus protect against disruption
of normal brain PUFA metabolism (Bousquet et al., 2008).
Meanwhile, a significant enrichment was found in plasma and
RBC, which would be consistent with the view that blood
lipid levels may act as a biomarker in neurodegenerative
disorders (for review see Dyall, 2015). Of note, these it cannot
be excluded that the peripheral changes could be secondary
to the general state of the animals, rather than to the
treatment.
Having ascertained the neuroprotective effects of TG-
DHA in cell models, we studied an animal model, the 6-
OHDA-lesioned mouse. We performed the 6-OHDA lesion
in the striatum as it has been reported that striatal lesions
lead to reliable, effective and retrograde degeneration of
dopaminergic neurons within the substantia nigra pars compacta
(Bagga et al., 2015; Becker et al., 2017), thus mimicking
better the disease-associated temporal dopaminergic denervation
(Deumens et al., 2002). Interestingly, we found that concomitant
and subsequent chronic administration of TG-DHA completely
prevented 6-OHDA-mediated striatal dopaminergic cell death;
furthermore, treated mice exhibited similar motor skills to those
of non-lesioned control mice. Various studies have investigated
the neuroprotective effects of n-3 PUFA in animal models of
PD. In contrast to our study, Coulombe and collaborators
(Coulombe et al., 2016) recently found no improvements in
motor behavior, but did observe partial neurorescue of the
dopaminergic system in 6-OHDA-lesioned mice fed with a
control or an n-3 PUFA-enriched diet for 6 weeks. However,
their study differed from ours in several important respects:
(i) Coulombe and collaborators performed a unilateral lesion
in the right striatum, whereas we lesioned both striatal
hemispheres; (ii) their treatment started 3 weeks after the
lesion, whereas we administered TG-DHA immediately after
6-OHDA lesion; (iii) they evaluated dopaminergic damage in
the substantia nigra pars compacta, whereas we assessed the
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FIGURE 5 | Impact of TG-DHA treatment on locomotor coordination. (A) Control (Veh) or 6-OHDA-lesioned mice, treated either with vehicle (Veh) or TG-DHA, were
placed on the beam and the time taken to traverse was considered an indication of their motor function. Results are expressed as means ± SEM (n = 12 animals).
∗∗∗P < 0.001 two-way ANOVA with Bonferroni’s post hoc test. (B) Linear regression and correlation between TH expression and time taken (sec) to traverse the
beam. Values are means ± S.E.M. (n = 12 animals).
lesion in striatum; and (iv) they used apomorphine-induced
contralateral rotation as the behavioral output, whereas we
evaluated motor coordination and balance through the beam
walking test. Therefore, while both experimental approaches were
suitable to assess parkinsonism in animal models of the disease,
our approach differed in three main respects: (i) prophylactic
TG-DHA administration; (ii) accurate measurement of motor
skills; and (iii) evaluation of dopaminergic denervation by
TH expression in the striatum. Therefore, our study provides
complementary information to that previously reported by
Coulombe and collaborators. In another study, Bousquet and
collaborators reported that animals receiving prophylactic n-3
PUFA from 2 to 12 months were resistant to MPTP lesions,
and no reduction in TH was observed (Bousquet et al.,
2008). In a subsequent study, they assessed the relationship
between brain-derived neurotrophic factor (BDNF) and the n-
3 PUFA-mediated neuroprotective effect using the same animal
model of parkinsonism. They found that n-3 PUFA pre-
treatment for 10 months increased BDNF mRNA expression
in the striatum, but not in the motor cortex of mice.
Furthermore, n-3 PUFA treatment increased BDNF protein
content in the motor cortex of parkinsonian animals. Overall,
these results suggest that n- 3 PUFA modulation of BDNF
expression may form part of the mechanism underlying n-
3 PUFA-mediated neuroprotection in an animal model of
parkinsonism (Bousquet et al., 2009). Conversely, in another
study on rats subjected to chronic n-3 PUFA supplementation
(over 90 days), it was observed that the 6-OHDA lesion
induced a significant loss of TH expression, and again only a
partial rescue of apomorphine-induced rotation was obtained
(Delattre et al., 2010). Given the foregoing, we conclude that
DHA consumption clearly correlates with partial or complete
neuroprotection, but it may depend on the region examined;
indeed, we observed large differences in the fatty acid profile
when comparing cortex and striatum. While all previous
studies have used behavioral tests that are not sufficiently
sensitive to examine motor skills, here we implemented the
beam walking test as a behavioral tool to assess DHA-
mediated neuroprotection. This test has previously been shown
to be useful to evaluate motor skills and balance in other
neurodegenerative pathologies, such as Huntington’s disease
(Luong et al., 2011), and we have now implemented it in a PD
animal model.
In sum, we have shown the beneficial effects of administering
TG-DHA on neural viability following 6-OHDA-induced
toxicity, the tight control of brain lipid content even after
dopaminergic denervation, and the utility of the beam walking
test to robustly evaluate parkinsonism. We conclude that the use
of TG-DHA as a neuroprotective agent in PD may constitute a
promising pharmacotherapeutic strategy.
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